{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:14:45Z","timestamp":1784139285576,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.juro.2011.04.073","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T01:03:12Z","timestamp":1311728592000},"page":"817-823","source":"Crossref","is-referenced-by-count":39,"title":["Factors Affecting Response to Bacillus Calmette-Gu\u00e9rin Plus Interferon for Urothelial Carcinoma in Situ"],"prefix":"10.1097","volume":"186","author":[{"given":"Henry M.","family":"Rosevear","sequence":"first","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lightfoot","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Birusingh","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Maym\u00ed","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Nepple","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National BCG\/Interferon Investigator Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2011.04.073_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2009","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2011.04.073_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(17)59645-7","article-title":"The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma","volume":"112","author":"Skinner","year":"1974","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib3","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2011.04.073_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O'Donnell","year":"2006","journal-title":"World J Urol"},{"issue":"suppl","key":"10.1016\/j.juro.2011.04.073_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000052386","article-title":"Treatment of superficial bladder tumors: achievements and needs","volume":"37","author":"Kurth","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-5347(17)45604-7","article-title":"Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder","volume":"135","author":"Herr","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","article-title":"Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule","volume":"149","author":"Melekos","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2011.04.073_bib10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(01)01539-4","article-title":"Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer","volume":"59","author":"Iori","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.04.073_bib12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib13","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib14","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","article-title":"Superficial bladder cancer: the role of interferon-alpha","volume":"159","author":"Belldegrun","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0090-4295(01)01187-6","article-title":"Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach","volume":"58","author":"Luciani","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.04.073_bib17","first-page":"1790","article-title":"Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy","volume":"10","author":"Punnen","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib18","first-page":"3189","article-title":"Treatment of BCG failures with intravesical BCG\/interferon: the University of Montreal experience","volume":"13","author":"Karakiewicz","year":"2006","journal-title":"Can J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2011.04.073_bib20","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.04.073_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0094-0143(21)00139-7","article-title":"Carcinoma in situ: comments on the pathobiology of a paradox","volume":"7","author":"Weinstein","year":"1980","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2011.04.073_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0090-4295(99)80047-8","article-title":"Risk factors in carcinoma in situ of the urinary bladder","volume":"45","author":"van Gils-Gielen","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.juro.2011.04.073_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","article-title":"Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression","volume":"141","author":"Herr","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.6004\/jnccn.2009.0004","article-title":"Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis","volume":"7","author":"Nese","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.juro.2011.04.073_bib29","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2011.04.073_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534711038547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534711038547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2011.04.073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T02:19:26Z","timestamp":1651198766000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2011.04.073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1016\/j.juro.2011.04.073"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2011.04.073","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}